Compare · DGX vs UNH
DGX vs UNH
Side-by-side comparison of Quest Diagnostics Incorporated (DGX) and UnitedHealth Group Incorporated (UNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DGX and UNH operate in Medical Specialities (Health Care), so they compete in similar markets.
- UNH is the larger of the two at $384.49B, about 16.6x DGX ($23.18B).
- Over the past year, DGX is up 24.8% and UNH is up 50.7% - UNH leads by 25.9 points.
- UNH has been more active in the news (28 items in the past 4 weeks vs 4 for DGX).
- Both have 25 recent analyst ratings on file.
- Company
- Quest Diagnostics Incorporated
- UnitedHealth Group Incorporated
- Price
- $209.89+0.22%
- $434.41+2.63%
- Market cap
- $23.18B
- $384.49B
- 1M return
- +4.40%
- +6.49%
- 1Y return
- +24.80%
- +50.71%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 4
- 28
- Recent ratings
- 25
- 25
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Latest DGX
- One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns
- Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
- SEC Form 4 filed by Director Wentworth Timothy C
- Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
- SEC Form 11-K filed by Quest Diagnostics Incorporated
- UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
- Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
- Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
- SVP, Clinical Solutions Kuppusamy Karthik exercised 8,147 shares at a strike of $124.22 and sold $1,629,400 worth of shares (8,147 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)
- CEO and President Davis J. E. sold $1,941,400 worth of shares (10,000 units at $194.14) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 132,423 units (SEC Form 4)
Latest UNH
- UnitedHealth upgraded by Robert W. Baird with a new price target
- UnitedHealth Group Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- UnitedHealth Group Reports Second Quarter 2026 Results
- UnitedHealthcare Launches New Spending Account Benefit, Putting More Choice in the Hands of Consumers
- Director Noseworthy John H was granted 206 shares, increasing direct ownership by 3% to 7,616 units (SEC Form 4)
- Director Montgomery Rice Valerie Md was granted 220 shares, increasing direct ownership by 3% to 7,876 units (SEC Form 4)
- Director Mcnabb Frederick William Iii was granted 250 shares, increasing direct ownership by 2% to 15,462 units (SEC Form 4)
- Director Gottlieb Scott was granted 210 shares, increasing direct ownership by 47% to 659 units (SEC Form 4)
- Director Gil Kristen was granted 206 shares, increasing direct ownership by 9% to 2,617 units (SEC Form 4)
- Director Garcia Paul R was granted 220 shares, increasing direct ownership by 6% to 3,906 units (SEC Form 4)